StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 17, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Sinovac Biotech's pe ratio was 5.1× on Feb 27, 2026, against 32.4× a year earlier. Over the last 5 years it ranged from 0.1× to 32.4×, with a median of 6.7×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Feb 27, 20265.1×+0.0
2025Dec 31, 20255.1×−27.3
2024Feb 29, 202432.4×+0.0
2023Dec 29, 202332.4×+32.3
2022Dec 30, 20220.1×−6.6
2021Dec 31, 20216.7×−9.1
2020Dec 31, 202015.8×−3.2
2019Dec 31, 201919.0×+3.6
2018Dec 31, 201815.4×−22.6
2015Feb 27, 201538.0×−2.2
2014Dec 31, 201440.2×+30.4
2011Feb 28, 20119.8×+0.0
2010Dec 31, 20109.8×–

More Sinovac Biotech figures

See a number that looks wrong?